David Bellocq1,2, Vincent Pierre-Kahn3, Frédéric Matonti4, Carole Burillon5, Nicolas Voirin6,7, Corinne Dot8, Jad Akesbi9, Solange Milazzo10, Stéphanie Baillif11, Vincent Soler12, Benjamin Wolff13, Claire Scemama14, Ariane Malclès1,2, Michel Weber15, Laurent Kodjikian1,2. 1. Department of Ophthalmology, Croix-Rousse University Hospital, Hospices Civils de Lyon, University of Lyon I, Lyon, France. 2. CNRS UMR 5510 Mateis, Villeurbanne, France. 3. Department of Ophthalmology, Hôpital Foch, Suresnes, France. 4. Department of Ophthalmology, Nord Hospital, Aix Marseille University, Institut de Neurosciences de la Timone, CNRS/ UMR7289, Marseille, France. 5. Department of Ophthalmology, Edouard Herriot Hospital, University of Lyon I, Institut de Biologie et Chimie des Protéines, CNRS/ UMR5086, Lyon, France. 6. Hospices Civils de Lyon, Service de Biostatistique, Lyon, France. 7. Laboratoire de Biométrie et Biologie Evolutive, CNRS, UMR 5558, Equipe Biostatistique-Santé, Villeurbanne, France. 8. Department of Ophthalmology, Desgenettes military Hospital, University of Val de Grâce, Paris, France. 9. Department of Ophthalmology, XV XX Ophthalmic National Hospital Center, Paris, France. 10. Department of Ophthalmology, University of Picardie Jules Verne, CHU Amiens Picardie -Site Sud D408 Amiens cedex 1 80054 . France. Center n° 86 of network EVICR-net, Amiens, France. 11. Department of Ophthalmology, Saint Roch University Hospital, Nice Sophia Antipolis, France. 12. Department of Ophthalmology, University Hospital, Toulouse, France. 13. Centre Ophtalmologique Maison Rouge, Strasbourg, France. 14. Department of Ophthalmology, Fondation Rotschild, Paris, France. 15. Department of Ophthalmology, University Hospital of Nantes, Nantes, France.
Abstract
AIM: To assess the effectiveness of intravitreal dexamethasone implants for treating postsurgical macular oedema (PSMO) including Irvine-Gass syndrome and determining the predictive factors of treatment response. METHODS: Descriptive, observational, retrospective, consecutive, uncontrolled, multicentre, national case series. One hundred patients were included between April 2011 and June 2014, with a minimum of 1-year follow-up. Patients received dexamethasone implant 0.7 mg at baseline. Clinical characteristics, best-corrected visual acuity (BCVA), central subfield macular thickness (CSMT) and intraocular pressure were measured at each visit. The main outcome measure was the change in BCVA (Early Treatment of Diabetic Retinopathy Study (ETDRS) letters: L). An analysis of predictive factors of treatment response is also provided. RESULTS: Mean improvement in BCVA was 9.6 (±10.6) L at month 6 and 10.3 (±10.7) L at month 12 (p<0.001). The proportion of eyes with gains in BCVA of 15 or more letters was 32.5% and 37.5% at months 6 and 12, respectively. The mean reduction in CSMT was 135.2 and 160.9 µm at months 6 and 12, respectively (p<0.001). Thirty-seven per cent of patients did not need a second injection after the first injection during follow-up. The presence of at least one PSMO risk factor decreases the probability of a gain in visual acuity (VA) ≥10 L (p=0.006). Initial VA ≤50 L at baseline and non-naïve status decrease the probability of having only one injection during follow-up (p=0.044). CONCLUSIONS: The significant gain in BCVA from baseline achieved at month 6 was maintained at month 12 after intravitreal injection of dexamethasone implant. Naïve status seems to be a good predictive factor of treatment response. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
AIM: To assess the effectiveness of intravitreal dexamethasone implants for treating postsurgical macular oedema (PSMO) including Irvine-Gass syndrome and determining the predictive factors of treatment response. METHODS: Descriptive, observational, retrospective, consecutive, uncontrolled, multicentre, national case series. One hundred patients were included between April 2011 and June 2014, with a minimum of 1-year follow-up. Patients received dexamethasone implant 0.7 mg at baseline. Clinical characteristics, best-corrected visual acuity (BCVA), central subfield macular thickness (CSMT) and intraocular pressure were measured at each visit. The main outcome measure was the change in BCVA (Early Treatment of Diabetic Retinopathy Study (ETDRS) letters: L). An analysis of predictive factors of treatment response is also provided. RESULTS: Mean improvement in BCVA was 9.6 (±10.6) L at month 6 and 10.3 (±10.7) L at month 12 (p<0.001). The proportion of eyes with gains in BCVA of 15 or more letters was 32.5% and 37.5% at months 6 and 12, respectively. The mean reduction in CSMT was 135.2 and 160.9 µm at months 6 and 12, respectively (p<0.001). Thirty-seven per cent of patients did not need a second injection after the first injection during follow-up. The presence of at least one PSMO risk factor decreases the probability of a gain in visual acuity (VA) ≥10 L (p=0.006). Initial VA ≤50 L at baseline and non-naïve status decrease the probability of having only one injection during follow-up (p=0.044). CONCLUSIONS: The significant gain in BCVA from baseline achieved at month 6 was maintained at month 12 after intravitreal injection of dexamethasone implant. Naïve status seems to be a good predictive factor of treatment response. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Authors: Alejandro Gonzalez-De la Rosa; Jose Navarro-Partida; Juan Carlos Altamirano-Vallejo; Gerardo Daniel Jauregui-Garcia; Ricardo Acosta-Gonzalez; Miguel Angel Ibanez-Hernandez; Guadalupe Fernando Mora-Gonzalez; Juan Armendáriz-Borunda; Arturo Santos Journal: J Ocul Pharmacol Ther Date: 2019-09-05 Impact factor: 2.671
Authors: Matteo Fallico; Andrea Maugeri; Giovanni L Romano; Claudio Bucolo; Antonio Longo; Vincenza Bonfiglio; Andrea Russo; Teresio Avitabile; Martina Barchitta; Antonella Agodi; Francesco Pignatelli; Paola Marolo; Luca Ventre; Guglielmo Parisi; Michele Reibaldi Journal: Front Pharmacol Date: 2021-04-15 Impact factor: 5.810